Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Cash from Investing Activities for 6 consecutive years, with -$333000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 103.32% year-over-year to -$333000.0, compared with a TTM value of -$696000.0 through Dec 2025, down 114.25%, and an annual FY2025 reading of -$696000.0, down 114.25% over the prior year.
  • Cash from Investing Activities was -$333000.0 for Q4 2025 at Xeris Biopharma Holdings, down from -$71000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $36.6 million in Q4 2021 and bottomed at -$44.0 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is $6.5 million, with a median of $8.8 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities surged 404.92% in 2021, then crashed 754.84% in 2023.
  • Year by year, Cash from Investing Activities stood at $36.6 million in 2021, then tumbled by 74.95% to $9.2 million in 2022, then surged by 62.17% to $14.9 million in 2023, then crashed by 32.63% to $10.0 million in 2024, then crashed by 103.32% to -$333000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for XERS at -$333000.0 in Q4 2025, -$71000.0 in Q3 2025, and -$279000.0 in Q2 2025.